Modulators of sphingosine phosphate receptors
Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.
1. A compound of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound of claim 1 of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
3. The compound of claim 1 of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
4. The compound of claim 1 of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
5. The compound of claim 1 of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
6. The compound of claim 1 wherein the compound is in the form of a racemic mixture.
7. The compound of claim 1 wherein the compound is in the form of an isolated optical isomer.
8. The compound of claim 7 wherein the isolated isomer is at least about 90% by weight pure relative to its corresponding optical isomer.
9. The compound of claim 8 wherein the isolated isomer is at least 99% by weight pure relative to its corresponding optical isomer.
10. A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.
11. The composition of claim 10 wherein the composition is in oral solid dosage form.
12. The composition of claim 11 wherein the oral solid dosage form is a tablet or capsule.
13. A compound of the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.
14. The compound of claim 13 wherein the compound is in the form of a racemic mixture.
15. The compound of claim 13 wherein the compound is in the form of an isolated optical isomer.
16. The compound of claim 15 wherein the isolated isomer is at least about 90% by weight pure relative to its corresponding optical isomer.
17. The compound of claim 15 wherein the isolated isomer is at least 99% by weight pure relative to its corresponding optical isomer.
18. A composition comprising a compound of claim 13 in combination with a pharmaceutically acceptable carrier or diluent.
19. The composition of claim 18 wherein the composition is in oral solid dosage form.
20. The composition of claim 19 wherein the oral solid dosage form is a tablet or capsule.